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Abstract
Background: Lissencephaly, or smooth brain, is a severe congenital brain malformation that is thought to be
associated with impaired neuronal migration during corticogenesis. However, the exact etiology of lissencephaly
in humans remains unknown. Research on congenital diseases is limited by the shortage of clinically derived
resources, especially for rare pediatric diseases. The research on lissencephaly is further limited because gyration
in humans is more evolved than that in model animals such as mice. To overcome these limitations, we
generated induced pluripotent stem cells (iPSCs) from the umbilical cord and peripheral blood of two
lissencephaly patients with different clinical severities carrying alpha tubulin (TUBA1A) missense mutations
(Patient A, p.N329S; Patient B, p.R264C).
Results: Neural progenitor cells were generated from these iPSCs (iPSC-NPCs) using SMAD signaling inhibitors.
These iPSC-NPCs expressed TUBA1A at much higher levels than undifferentiated iPSCs and, like fetal NPCs, readily
differentiated into neurons. Using these lissencephaly iPSC-NPCs, we showed that the neurons derived from the
iPSCs obtained from Patient A but not those obtained from Patient B showed abnormal neurite extension, which
correlated with the pathological severity in the brains of the patients.
Conclusion: We established iPSCs derived from lissencephaly patients and successfully modeled one aspect of
the pathogenesis of lissencephaly in vitro using iPSC-NPCs and iPSC-derived neurons. The iPSCs from patients
with brain malformation diseases helped us understand the mechanism underlying rare diseases and human
corticogenesis without the use of postmortem brains.
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Background
Dysfunction in the complicated cellular dynamics in-
volved in the development of the cerebral cortex causes
various congenital brain malformations during different
stages of the development of the central nervous sys-
tem (CNS) [1]. The two major modes of development
in the human cerebral cortex are tangential and radial
expansion. Tangential expansion evolves as the number
of progenitor cells increases, as observed recently in
the outer subventricular zone radial glia of gyrencepha-
lic species including humans [2, 3]. A decreased num-
ber or abnormal division of progenitor cells leads to
microcephaly, or small brain. Radial expansion depends
on neuronal migration in a basal to apical direction
along the processes of the radial glia, and dysfunction
in this process impairs corticogenesis in lissencephaly.
Lissencephaly, with disturbed cerebral cortical lamin-
ation, is one of the most severe brain malformations. In
lissencephaly, the surface of the brain appears smooth
owing to insufficient gyration, which is why this condi-
tion is called smooth brain. Lissencephaly is mainly
caused by mutations in genes, many of which are in-
volved in microtubule function. In addition to the genes
encoding microtubule-associated proteins, alpha tubu-
lin (TUBA1A) mutations have recently been shown to
cause abnormal neuronal migration [4]. In humans,
TUBA1A mutations have been identified in lissence-
phaly patients whose brains showed a smooth surface
owing to severely impaired lamination of the cerebral
cortex [4–6]. Lissencephaly in humans is an extremely
rare disease, and lissencephaly patients often die within
a few years, thus making it difficult to obtain viable
patient-derived cells including neurons. This limitation
has greatly restricted the complete elucidation of the
etiology of lissencephaly in humans.
Therefore, to investigate the pathogenic mechanisms
underlying lissencephaly in humans, we established in-
duced pluripotent stem cells (iPSCs) from lissencephaly
patients. Using neural progenitor cells and neurons gen-
erated from patient-derived iPSCs, we aimed to elucidate
the disease pathology and to develop novel therapies.
Methods
Generation of iPSCs
Umbilical cords collected from Patient A with the
p.N329S TUBA1A mutation (Fig. 1) and from vaginally
delivered full-term fetal adnexa of healthy volunteers
(male) were digested with collagenase I (Life Technologies,
Carlsbad, CA, USA) and dispase (Life Technologies) for
30 min at 37 °C. The cells liberated from the tissue were
then collected by centrifugation and seeded in T75 flasks
in Dulbecco’s modified Eagle’s medium/nutrient mixture
F-12 (DMEM/F12) (Sigma-Aldrich, St. Louis, MO, USA)
containing 10 % fetal bovine serum (FBS), 15 mM HEPES,
and antibiotic-antimycotic solution (Life Technologies)
[7]. Umbilical cord-derived stromal cells (UCCs) were
passaged after 1 week and used for iPSC generation after
3–5 passages.
Fig. 1 Magnetic resonance imaging (MRI) of two patients. a, b Patient A (p.N329S TUBA1A mutation) shows lissencephaly with cerebellar hypoplasia.
Thin cerebral mantle and agyric cerebral cortices (arrow in figure a) are observed without an anterior-posterior gradient. The corpus callosum is not
present (arrow in figure b). c, d Patient B (p.R264C TUBA1A mutation) shows pachygyria with a posterior-anterior gradient (arrow in figure c). Cerebellar
and brain stem hypoplasia are not as clear as in Patient A (arrowhead in figure d). The corpus callous is present (arrow in figure d). e Schematic
structure of TUBA1A is represented based on a previous report [34]. Both missense mutations in TUBA1A were located in the intermediate
domain of TUBA1A. f Three-dimensional structure of the TUBA1A protein. Helices are presented as cylinders. The arrows show the residue of
each mutation. The p.N329S mutation was located on alpha-helix H10, which formed the interface with beta-tubulin. The p.R264C mutation
was located between alpha-helix H8 and the beta sheet, which could be responsible for providing stability to the tertiary structure
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Peripheral blood mononuclear cells (PBMCs) from
Patient B with the p.R264C TUBA1A mutation (Fig. 1)
and from a healthy adult volunteer were isolated using
Ficoll-Paque (GE Healthcare, Buckinghamshire, UK) ac-
cording to the manufacturer’s instructions. The isolated
PBMCs were activated with immobilized anti-CD3
monoclonal antibodies (Orthoclone OKTR3 Injection,
Janssen-Kyowa, Tokyo, Japan) and expanded in soluble
interleukin (IL)-2-containing ALyS203 medium (NIPRO,
Japan) with 10 % FBS as previously described, with
minor modifications [8]. In this study, we used the human
iPSC line (201B7) [9] derived from human dermal fibro-
blasts from the facial dermis of a 36-year-old Caucasian
female as the control (obtained from the RIKEN cell bank
(Tsukuba, Japan)).
For iPSC generation, reprogramming episomal vectors
(see below) were nucleofected using Amaxa Nucleofector
I (a Neonatal Fibroblast Nucleofector Kit with the U-020
program for UCCs and a Human T cell Nucleofector Kit
with the T-023 program for PBMCs; Lonza, Basel,
Switzerland). Plasmids were used with combinations of
pCXLE-hOct3/4-shp53, pCXLE-hUL, and pCXLE-hSK
[10] for UCCs and PBMCs [11] or pCEB-hSKO and
pCEB-hULG for UCCs. All the plasmids were graciously
provided by Dr. Keisuke Okita and Prof. Shinya Yamanaka
(Kyoto University, Kyoto, Japan). The subsequent proce-
dures, including colony isolation and propagation, were
performed as previously described [12]. The generated
iPSCs were characterized using immunocytochemistry for
the pluripotency-associated transcription factors OCT3/4
and NANOG; quantitative RT-PCR for the marker genes
OCT3/4, SOX2, NANOG, ZFP42, and DNMT3B; and PCR
according to protocols provided by the Center for Devel-
opmental Biology (RIKEN, http://www.cdb.riken.jp) and
the Center for iPS Cell Research and Application (Kyoto
University, https://www.cira.kyoto-u.ac.jp) to confirm that
the episomal vectors did not persist.
The teratoma formation assay for the iPSCs was per-
formed with subcutaneous transplantations into NOD/
Shi-SCID IL2Rγ null (NOG) mice [12, 13] in the Animal
Facility of the CIEA (Central Institute for Experimental
Animals, Kawasaki, Japan), in accordance with the
guidelines of the Animal Care Committee at CIEA, and
was approved by the Animal Care Committee at CIEA
(No.11029A). The genomic sequences of TUBA1A were
confirmed using previously reported methods [6].
The human embryonic stem cell line KhES1 [14] was
propagated at Keio University in accordance with Japanese
guidelines for the utilization of human embryonic stem
cells with the approval of the Ministry of Education,
Culture, Sports, Science and Technology of Japan and
the ethical committee of Keio University. RNA samples
from the KhES1 cells were isolated using an RNeasy
minikit (QIAGEN, Valencia, CA, USA) and were used
as a standard for quantitative RT-PCR. Summaries of
the donor information and radiological images are
shown in Table 1 and Fig. 1a–d, respectively. Both the
TUBA1A mutations in these patients were located in
the intermediate domain of TUBA1A, as shown in the
schematic illustration in Fig. 1e. A karyotyping analysis
was performed using conventional Giemsa staining and
G-banding in all the generated iPSCs as described
previously [12].
Gene and protein analyses
The sequences of the TUBA1A gene in this report are
based on the sequences obtained from GenBank (Acces-
sion NM_006009). The protein structure of TUBA1A
[15] was obtained from Protein Data Bank Japan (PDBj:
1JFF), and the illustration was generated using CueMol2
(http:/http://www.cuemol.org/en/).
Neural induction by dual SMAD inhibition and neurosphere
propagation
The highly efficient dual inhibition of SMAD signaling
was used for neural induction of the iPSCs [16]. Briefly,
the iPSCs cultured in growth-factor-reduced (GFR)
Matrigel (BD Biosciences, San Diego, CA, USA)-coated
dishes were collected and suspended in low-attachment
dishes (Primesurface, Sumitomo Bakelite, Tokyo, Japan)
to form embryoid bodies (EBs). For neural induction,
the EBs were subsequently cultured in DMEM/F12 con-
taining 5 % B27 supplement (Life Technologies), 5 % N2
supplement (Life Technologies), 20 ng/ml recombinant
human (rh) basic fibroblast growth factor (bFGF)
(Wako, Osaka, Japan), 10 μM SB431542 (SB; Sigma-
Aldrich), and 1 μM dorsomorphin (DSM; Wako) for
2 weeks under 5 % O2. To obtain neural progenitor cells
(NPCs) as neurospheres, the cell aggregates were mech-
anically dissociated and cultured in DMEM/F12 contain-
ing 2 % B27 supplement (Life Technologies), 20 ng/ml
rh-basic fibroblast growth factor (bFGF; PeproTech,
Rocky Hill NJ, USA), 20 ng/ml rh-epidermal growth fac-
tor (EGF; PeproTech), 10 ng/ml rh-leukemia inhibitory
factor (LIF; Millipore, Billerica, MA, USA), and 5 μg/ml
heparin (Sigma-Aldrich). The neurospheres were passaged
before the center of the spheres darkened, typically every
12–14 days as described previously [17].
Differentiation of the iPSC-derived neurospheres
At approximately passage six, the neurospheres were
plated onto GFR Matrigel (BD)-coated dishes in neuro-
basal medium (Life Technologies) containing 2 % B27
supplement (Life Technologies) and 2 mM L-glutamine
(Life Technologies) (differentiation medium). For the
PiggyBac vector transfection experiments, iPSC-derived
neurospheres were used at stages beyond six passages
when the regional identities could be caudalized and
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stably propagated. For differentiation in dissociated cul-
ture, the neurospheres were dissociated using TrypLE
Select (Life technologies) for 5 min at 37 °C, and the
dissociated iPSC-NPCs were seeded onto GFR-Matrigel
(BD)-coated 96-well plates and 6-well plates in differenti-
ation media.
Quantitative RT-PCR
RNA was extracted from the aggregates and neurospheres
using an RNeasy Mini Kit (QIAGEN) and DNase set (QIA-
GEN), and cDNAs were synthesized using PrimeStarRT
Reagent Kits (Takara Bio, Shiga, Japan). Quantitative PCR
was performed using a PowerSYBR Green PCR Mix (Life
Technologies) and an ABI7300 Real-time PCR system (Life
Technologies) using gene-specific primer pairs (Additional
file 1: Table S1). The expression (Ct values) of each gene
was normalized to that of an internal control, and the nor-
malized expression was compared using the ΔΔCt method
as previously described [18]. As a human telencephalic
control, 201B7 iPSC-derived telencephalic SFEB (serum-
free floating-culture of embryoid body-like) aggregates at
day 25 [19] were used. GDC90 human glial cell lines were
used as a human glial cell control [20].
Visualization of the neurite extension of neurons
derived from iPSCs of lissencephaly patients using the
glia-supported neurite extension method
We used the human glial cell line GDC90 as a scaffold
[20] to support the robust differentiation and neurite
extension of the iPSC-derived neurons. To distinguish
glial cell lines and iPSC-derived neural progenitor cells
(iPSC-NPCs) and to illustrate the morphology of the
neurites migrating from each iPSC-NPC-derived young
neuron, the CAG promoter-driven [21] PiggyBac vector
pPB-CAG-EGFP-neo [20] was nucleofected into the
iPSC-derived neurospheres using Amaxa Nucleofector I
(Lonza) as previously described [20]. After positive se-
lection using Geneticin at a concentration of 200 μg/ml
(Life Technologies), the enhanced green fluorescent
protein (EGFP)-labeled iPSC-NPCs were used for fur-
ther analyses.
To measure the neurites migrating from the neuro-
spheres, iPSC-NPCs (5 × 103 cells or 2.5 × 103 cells for
time-lapse imaging) and GDC90s (5 × 103 cells or 7.5 ×
103 cells for time-lapse imaging) were seeded and re-
aggregated in low-attachment 96-well plates with spindle-
shaped bottoms (Sumitomo Bakelite). After 24 h, the
re-aggregated spheres were plated onto GFR-Matrigel-
coated glass-bottom dishes in differentiation medium. In
some experiments requiring the visualization of the glial
cell line, tdTomato-labeled GDC90s [20] were used.
To quantify the behavior of the iPSC-NPCs derived
from lissencephaly patients, the length of the EGFP-
fluorescent neurites extending from the soma of the
iPSC-NPCs existing at the edge of the fluorescent clus-
ters was measured using ImageJ software on day 5.
Time-lapse images during the differentiation and mi-
gration of the control and lissencephaly iPSC-derived
neurons were acquired using an IncuCyte ZOOM HD
(Essen BioSciences, Ann Arbor, MI, USA) every 4 h.
The video files were exported in AVI format at six
frames per second.
Immunocytochemistry and immunohistochemistry
Undifferentiated iPSCs, forebrain-committed neurons,
and neurospheres were fixed in 4 % paraformaldehyde
and stained using primary and secondary antibodies as
described below. The samples were examined using a
confocal laser-scanning microscope (LSM510, Carl
Zeiss, Hallbergmoos, Germany). The following primary
antibodies were used (host, dilution, manufacturer):
neuronal class III β-tubulin (TUJ1; mouse, 1:500, Covance,
Princeton, NJ), brain lipid-binding protein (BLBP; rabbit,
1:500, Millipore), GFAP (rabbit, 1:80, Sigma-Aldrich),
SOX1 (mouse, 1:500, BD Pharmingen), NESTIN (rabbit,
1:500 [22] and mouse, 1:500, Millipore), GFP (mouse,
1:500, Clontech, Palo Alto, CA, USA), doublecortin (DCX;
rabbit, 1:500, Cell Signaling), OCT-4 (mouse, 1:200, BD),
NANOG (rabbit, 1:200, ReproCELL), TRA-1-60 (mouse,
1:200, Chemicon), SSEA-3 (rat, 1:200, Chemicon),
SSEA-4 (mouse, 1:200, Chemicon), and TRA-1-81
(mouse, 1:200, Chemicon). The following secondary
antibodies were used: goat anti-mouse IgG Alexa Fluor
488 (1:1000, Molecular Probes), goat anti-rabbit IgG
Alexa Fluor 568 (1:1000, Molecular Probes), goat anti-
rabbit IgG Alexa Fluor 488 (1:1000, Molecular Probes),
goat anti-mouse IgG Alexa Fluor 648 (1:1000, Molecular
Probes), goat anti-mouse IgM Alexa Fluor 568 (1:1000,
Molecular Probes), goat anti-rat IgM Alexa Fluor 488
(1:1000, Molecular Probes), and goat anti-rabbit IgG Alexa
Fluor 648 (1:1000, Molecular Probes).
Results
Generation of iPSCs derived from lissencephaly patients
and control iPSCs
As a first step in generating iPSCs from patients with
lissencephaly, gene-transferred UCCs and PBMCs were
re-seeded onto the feeder cells of mouse embryonic fi-
broblasts on day 7 by using nucleofection, and both
UCCs and PBMCs were reprogrammed 3 weeks after
replating. In the established patient-derived iPSC lines,
the colonies appeared like those of human embryonic
stem cells (Fig. 2a). TUBA1A sequencing showed the het-
erozygous mutated sequence c.986A >G or c.790C > T
(Fig. 2b), and immunocytochemical analyses confirmed
the expression of pluripotent marker genes (Fig. 2c).
Karyotype analyses showed that these lines maintained a
normal karyotype (Fig. 2d). We also established iPSCs
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(ONH-UCCiPS1#1 from UCC from a healthy volunteer
using the same procedure as described above (Additional
file 2: Figure S1A).
Quantitative real-time PCR showed that these lines
expressed pluripotent cell markers similar to those
expressed in the human embryonic stem cells KhES1
(Additional file 2: Figure S1B). These results showed that
the newly generated iPSCs differentiated into three germ
layers, suggesting that they were pluripotent. PCR analysis
of the genomic DNA confirmed that the episomal vector
was absent in these iPSCs (Additional file 2: Figure S1C).
A teratoma formation assay using subcutaneous trans-
plantation into severely immunodeficient NOG mice was
conducted to test for differentiation (Additional file 2:
Figure S1D). Collectively, these findings confirmed that
the established human iPSC clones in the present study
met the general criteria for human iPSCs.
Generation of iPSC-NPCs using dual SMAD inhibition and
neurosphere culture
After dual SMAD inhibition, the EBs containing neural
progenitor cells were grown for 14 days. Following EB dis-
sociation, proliferative iPSC-NPCs were generated using
neurosphere culture with serum-free medium containing
bFGF-2, EGF, and LIF (Fig. 3a). Quantitative RT-PCR ana-
lysis for TUBA1A, 1B, and 1C showed that only 1A
showed remarkable activation during neural induction,
suggesting that phenotypic analyses should be performed
Fig. 2 Characterization of control- and patient-derived induced pluripotent stem cells (iPSCs). a Phase contrast images of the patient-derived
iPSCs (scale bar = 500 μm) showed that both patient-–derived iPSCs had the typical morphology of human pluripotent stem cells on mouse
embryonic fibroblast (MEF). b Sequencing of α tubulin 1A (TUBA1A) in the genomic DNA of the iPSCs showed that the generated iPSCs had
missense mutations in TUBA1A (c.986A > G in patient A-derived iPSCs, and c.790C > T in patient B-derived iPSCs); these base substitutions cause
the p.N329S mutation and p.R264C mutation, respectively, in the TUBA1A protein. c Immunocytochemistry for the marker proteins OCT3/4 and
NANOG of pluripotent stem cells (scale bar = 50 μm). All the generated iPSCs expressed both OCT3/4 and NANOG. All the iPSCs derived from the
lissencephaly patients (TUBA1A-iPS-A#1,3, TUBA1A-iPS-B-#1,2) expressed both OCT3/4 and NANOG. d Giemsa staining of the generated iPSCs.
Karyotype of the patient-derived iPSCs showed that they had normal 46 XY karyotype
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Fig. 3 (See legend on next page.)
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in the neurospheres and not in the undifferentiated iPSCs
(Fig. 3b). The cells in the neurospheres homogeneously
expressed the NPC markers SOX1 and NESTIN (Fig. 3c),
as confirmed by immunocytochemistry, which indicated
that these cells contained NPCs with high purity. Further-
more, quantitative RT-PCR analyses showed that the
neural marker N-Cadherin and the NPC markers SOX1
and BLBP were highly expressed in each neurosphere
(Fig. 3d). Together, these data indicate that iPSC-NPCs
could be generated by dual SMAD inhibition and could
be proliferated as neurospheres.
TUBA1A mutation-associated lissencephaly is charac-
terized by cerebellar hypoplasia and often involves the
hypoplasia of the brain stem, including the midbrain
and pons. Thus, it is important to determine the re-
gional identity of the neurospheres generated using this
method. We therefore performed expression analyses
for the region-specific markers.
Interestingly, these propagated neurospheres expressed
forkhead box G1 (FOXG1; a forebrain marker) at a lower
level and gastrulation brain homeobox 2 (GBX2; a hind-
brain marker) a higher level compared with the miniature
brain called “SFEB”, which was used as a human telen-
cephalic control and was generated using previously
described methods [19]. This result indicated that these
neurospheres belonged to the caudal region, which in-
cludes the hindbrain (Fig. 3e).
Soon after differentiation, these neurospheres contained
glial, neuronal, and neural progenitor cells, all of which
play important roles in fetal CNS development. When the
neurospheres were plated, βIII tubulin-positive neuronal
cells and several BLBP-positive glial fibers spread toward
the outside. BLBP-positive fibers are highly polarized and
consist of long processes that extend out of the neuro-
spheres, similar to what was observed for radial glial cells
during CNS development (Fig. 3f-k).
At first, we simply compared the morphology of the
differentiating neurospheres on Matrigel-coated dishes
during early passages (6–8 passages) when the BLBP-
positive glial fibers were often observed. From these
neurospheres, many neurites extended together with
BLBP-positive glial fibers after 12 days (Fig. 3f-k).
Interestingly, the neurites and glial fibers derived from
the iPSC-NPCs of the lissencephaly patient A (with the
p.N329S TUBA1A mutation) did not extend radially and
displayed a shorter morphology (Fig. 3f-g). In contrast, the
neuronal cells and glial fibers derived from the iPSC-
NPCs from patient B carrying the p.R264C TUBA1A mu-
tation projected radially (Fig. 3h-i). We believe that these
results might be associated with the patient’s pathology.
However, quantitative analyses of neuronal morphology
was technically challenging due to significant increases in
cell density during the 12 days of in vitro differentiation
required. Furthermore, undifferentiated NPCs persisted in
the center of the neurospheres and continued to produce
newborn neurons, which would further complicate quan-
titative analyses of neuronal morphology such as Sholl
analysis.
The number of BLBP-positive glial cells in the neuro-
spheres was low and varied between neurospheres and cell
lines, which is consistent with the results of quantitative
RT-PCR for BLBP (Fig. 3d). To promote the differenti-
ation of NPCs [23] and to reduce variation, establishing
cultures with comparable glial content is critical. However,
propagation using conditions conducive for neurospheres
tends to make the iPSC-NPCs neurogenic rather than
gliogenic [24, 25] (Additional file 3: Figure S2), and the
precise control of the glial differentiation propensity of the
iPSCs remains technically difficult. Therefore, we supple-
mented the cultures with human glial cells in order to
induce robust and rapid differentiation of the iPSC-NPCs.
Glia-supported neurite extension with fluorescently
labeled iPSC-NPCs in neurospheres
Genetic labeling with a PiggyBac transposon system
was used to establish stable fluorescent iPSC-NPCs to
(See figure on previous page.)
Fig. 3 Generation of neurospheres from the induced pluripotent stem cells (iPSCs). a Schema of neural induction and neurosphere generation.
Neural induction using dual SMAD inhibition and subsequent neurosphere cultures were conducted to obtain the neurospheres. After 2 weeks
of neural induction, the embryoid bodies (EBs) were dissociated and cultured in a medium containing bFGF, EGF, and LIF (scale bar = 50 μm).
Representative photographs of EBs and neurospheres were derived from Patient A. b Quantitative RT-PCR for each TUBA1 isoform. Through neural
induction, only TUBA1A expression was greatly increased. Changes in the expression of each TUBA1 isoform were different (relative to the
expression in the undifferentiated iPSCs (201B7), fold change ± SD, n = 3, technical duplicates). c Immunostaining of each neurosphere (within
12 h after plating in neurosphere medium). Ubiquitous staining for the NPC markers NESTIN and SOX1 (scale bar = 50 μm) was observed in
each cell. d Quantitative RT-PCR showed that the neurospheres expressed the neural marker genes N-cadherin (CDH2) and α tubulin 1A
(TUBA1A) and the progenitor cell marker SOX1, all of which are expressed in the human neural stem cell (hNSC) line. The radial glial marker
brain lipid-binding protein (BLBP) was also expressed (relative to the expression in the undifferentiated iPS, fold change ± SD, n = 3, technical
duplicates). e Quantitative RT-PCR showed that the neurospheres had a caudalized regional identity characterized by high gastrulation brain
homeobox 2 (GBX2) expression and low Forkhead box protein G1 (FOXG1) expression (relative to the expression of SFEB used as human forebrain
control, fold change ± SD, n = 3, technical duplicates). f–k Spontaneous differentiation of the neurospheres. In 12 days, the βIII tubulin-positive neurites
and few BLBP-positive radial glial-like fibers had migrated radially from the neurospheres (scale bar = 200 μm). Poorly ordered neurites and
BLBP-positive radial glial-like fibers were observed in the TUBA1A-iPS-A-derived neurospheres (f–g). Radially extending neurites and BLBP-positive
radial glial-like fibers were observed in the TUBA1A-iPS-B-derived neurospheres (H–I) and control iPSC-derived neurospheres (j-k)
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distinguish them from glial cells (Fig. 4a). The iPSC-NPCs
were easily propagated by neurosphere culture, enabling
the transfection, selection, and propagation of fluorescent
cells. The iPSC-NPCs that were co-cultured with the
GDC90 cells rapidly polarized and extended their neurites
radially compared with those that were grown in the
absence of glial cells (Fig. 4b–d and Additional files 4 and
5: Movies S1 and S2). Immunocytochemistry showed that
most of the EGFP-positive (iPSC-NPC-derived) neurites
expressed DCX, which is a marker for young migrating
neurons (Fig. 4e). Time-lapse imaging showed that the
EGFP-positive neurites projected radially, and that some
of their somas were pulled up from the core of the neu-
rosphere in translocation-like movements in 12 days
(Additional files 5 and 6: Movies S2 and S3).
Analyses of extending neurites using glia-supported
neurite extension methods
The behaviors of the patient-derived and control iPSC-
NPCs were evaluated using the glia-supported neurite ex-
tension method. The measurement of neurite extension
after 5 days showed that neurite extension in iPSC-NPCs
derived from the patient with the p.N329S TUBA1A mu-
tation was severely inhibited (Fig. 4f–g and l, Additional
files 7 and 8: Movies S4, S5). These data suggest that neur-
onal cells that differentiated from the iPSC-NPCs with the
p.N329S TUBA1A mutation had an immature morph-
ology compared with those derived from the control
iPSC-NPCs. We believe that this phenotype corresponded
to the pathology of the developing brain because neuronal
cells initially polarize from NPCs and migrate toward the
cortical plate using various types of neurites, including the
leading process and basal process.
This observation was also supported by the results of
our experiment using human fetal forebrain-derived
NPCs, in which we introduced the CMV early enhancer/
chicken beta actin (CAG) promoter-driven p.N329S mu-
tant TUBA1A using the PiggyBac transposon based vector
system. The overexpression of p.N329S mutant TUBA1A
significantly reduced neurite extension of human NPCs
(Additional file 9: Figure S3, Additional file 10: Supple-
mentary method), suggesting that lissencephaly related to
the p.N329S TUBA1A mutation was caused by a
dominant-negative effect. Together with the results of our
experiments described above, we concluded that we had
successfully modeled one aspect of the pathology of lissen-
cephaly in vitro using patient-derived iPSC-NPCs with the
p.N329S TUBA1A mutation.
In contrast, we did not identify any phenotypic differ-
ence between the iPSC-NPCs with a p.R264C TUBA1A
mutation and those derived from the controls (Fig. 4h–k,
Additional file 11: Movie S6). One reason for this result
may be the disease severity of the patient. The corpus
callosum was missing in Patient A (with the N329S
mutation), (Fig. 1a-b, Fig. 4m) whereas it is detectable in
Patient B (with the p.R264C mutation), as determined
from the MR images (Fig. 1c-d, Fig. 4n), suggesting that
neurite extension was not as severely affected in Patient B
as in Patient A. This finding is consistent with our present
in vitro results obtained by measuring neurite extension
(Fig. 4l). Importantly, this result was also consistent with
the gradient in the pathology along the cephalic-caudal
axis, as observed in the patients. The brain stem and thal-
amus, which have a regional identity similar to that of our
iPSC-NPCs, did not appear hypoplastic in the MR images
obtained from Patient B (Fig. 1d, Table 1).
Overall, the p.N329S TUBA1A mutation observed in
Patient A showed reduced neurite extension that was
caused by mutated tubulin in a dominant-negative man-
ner. In contrast, the neurons generated from the iPSCs
from Patient B with the p.R264C TUBA1A mutation
showed no overt defects in neurite extension. This dif-
ference was consistent with the radiological pathology of
the TUBA1A lissencephaly patients.
Discussion
In the present study, we established iPSCs from an easily
accessible cell source from patients with lissencephaly
and successfully characterized the abnormalities of the
iPSC-derived neurons in vitro. Recent progress in cell
reprogramming methods enabled us to generate iPSCs
from a variety of cell sources [9, 11, 26]. For research on
human congenital brain malformations, the utility of
patient-derived iPSCs overcomes the hurdles that arise
owing to the lack of availability of patient-derived cells
in extremely rare diseases. Furthermore, we successfully
converted these cells into expandable and easy-to-handle
iPSC-NPCs using neurosphere culture technology; these
resources will be useful in human congenital malforma-
tion research in the future.
Lissencephaly is often caused by mutations in
microtubule-associated genes [27]. Polarized neuronal
cells depend on the microtubule pathway, whereas
non-polarized cells depend primarily on the driving
force of actin-myosin contraction. To model lissence-
phaly pathology in the iPSC-NPCs, the dynamic behav-
ior of the polarized neuronal cells must be visualized.
Spontaneously differentiating neurospheres showed
extensions of small proportions of BLBP-positive radial
fibers and aligned βIII tubulin-positive neurons. In our
simple assay, randomly oriented neurons migrated from
the neurospheres generated from the iPSCs with the
p.N392S TUBA1A mutation, which might partially re-
flect the in vivo pathology of the patients with TUBA1A
mutation-associated lissencephaly. To reduce the vari-
ation associated with the glial content of each neurosphere,
we used a human glial cell line for robust and rapid
neuronal differentiation. Moreover, we could observe the
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Fig. 4 (See legend on next page.)
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characteristics of the patient-derived neurons themselves
without the effects of the endogenous glial cells, which
might be susceptible to the effects of mutated TUBA1A
or the secondary effects of abnormal neuron-mediated
morphological changes that may spoil endogenous glial
scaffolds [28]. We also introduced a fluorescent protein
into the iPSC-NPCs to observe the behavior of the indi-
vidual cells using the PiggyBac transposon system. Inter-
estingly, the control iPSC-NPCs in this glial cell scaffold
rapidly differentiated into polarized neuronal cells with ra-
dially extending neurites. Using this system, we found that
the neurite extension from the iPSC-NPCs with the
p.N329S TUBA1A mutation was inhibited, whereas the
iPSC-NPCs carrying the p.R264C mutation showed no ap-
parent abnormality, indicating agenesis of the corpus cal-
losum in Patient A with the N329S mutation. This
observation suggested that patient-derived iPSC-NPCs
could recapitulate the neurite extension process in the pa-
tient brain. Furthermore, neuronal cells with short neur-
ites were also considered immature. Although we have no
histological data for these patients, these neurons were
considered similar to those of the patient brain because a
differentiation defect manifested by immature neurons
and persistent radial glia was reported previously in the
TUBA1A lissencephaly patient brain [27]. Based on our
data from the iPSC-derived NPCs, we concluded that the
pathology of p.N329S TUBA1A lissencephaly might start
from the steps of differentiation or polarization from
neural progenitor cells, leading to a migration defect in
young neurons and lamination defects in the cerebral
cortex. We suspect that p.N329S TUBA1A destabilizes
tubulin heterodimer formation by decreasing the num-
ber of hydrogen bonds between alpha- and beta-tubulin
in the neuronal cells that express abundant TUBA1A
for neurite extension [5]. This hypothesis is consistent
with the dominant-negative action of p.N329S mutant
TUBA1A on neurite extension, determined from the
overexpression experiments (Additional file 9: Figure S3).
However, considering its effects on the phenotype, the ef-
fect of overexpressing the mutant gene would be artificial.
Therefore, to investigate the role of N329S, R264C, and
other mutations in the disease-related phenotype, further
biochemical characterizations, in patient-derived iPSCs
and isogenic iPSCs introduced with these mutations by
genome editing, is required in our future experiments.
As shown above, we successfully recapitulated one as-
pect of the pathology of lissencephaly, but the import-
ant question of whether neurons derived from a
lissencephaly patient can migrate normally has not been
answered. The disorganized lamination of the cerebral
cortex in lissencephaly patients cannot be easily ex-
plained only by the delayed differentiation of neural
progenitor cells or the delay in polarization before
neuronal migration. To answer this question, further
experiments involving the direct observation of migrat-
ing human iPSC-derived cortical neurons are needed.
We have already generated a miniature brain from
iPSCs derived from a patient with severe lissencephaly.
However, unexpectedly, we found young cortical neurons
located outside the germinal layer (data not shown). The
exact mechanism of cortical layer formation in vitro needs
to be determined before interpreting this result.
We observed translocation-like movements in this
study, which led us to believe that our co-culture sys-
tem might be useful in the neuronal migration of iPSC-
derived telencephalic neurons.
Consistent with the MR images of the lissencephaly
patient B, who had a less severe phenotype, iPSC-NPCs
with the p.R264C TUBA1A mutation showed an almost
normal neurite extension, although it is possible that the
sensitivity of our assay system was not sufficient to
detect the slight change in the phenotype. In contrast to
(See figure on previous page.)
Fig. 4 Glia-supported neurite extension method for fluorescently labeled induced pluripotent stem cell (iPSC)-derived neurospheres. a Schema of
the glia-supported neurite extension method with fluorescently labeled iPSC-derived neurospheres. b,c Effect of the glia-supported neurite extension
method on the fluorescently labeled iPSC-derived neurospheres. After 3 days, the non-polarized cells spread in a disordered manner without a glial cell
line; however, using glia-supported neurite extension methods (with GDC90), the differentiating neurites were found to migrate from the neurospheres
in a radial and orderly manner (scale bar = 300 μm). Rapid and straightforward extension of the neurites was easily observed using strong
EGFP fluorescence. d Fluorescence and phase contrast merged images of the glia-supported neurite extension method using EGFP-labeled
iPSC-derived neurospheres and tdTomato-labeled human glial GDC90 cells (scale bar = 200 μm). e Immunostaining for the young neuron marker
doublecortin (DCX) showed that the neurites extending on the tdTomato-positive human glial cells were also stained with EGFP (scale bar = 50 μm).
f–k EGFP fluorescence of the extending neurites observed using the glia-supported neurite extension method on day 5 after plating on the dish.
Patient A (p.N329S)-derived neural progenitor cells (NPCs) showed poor neurite extension (f–g) compared to the Patient B (p.R264C)-derived (h-i) or
healthy control iPSC-derived NPCs (j–k) (scale bar = 200 μm). l Length of EGFP-positive neurites extending from the neurospheres (μm: mean ± SEM).
Boxplot graph illustrating median, first quartile, and third quartile with each outliner plotted. (**p < 0.01, one-way ANOVA followed by Dunnett’s
test. n = 269, 277, 374, 369, 338, and 213 in A#1, A#3, B#1, B#2, 201B7 (control), and UCCiPS1#1, respectively. Statistical analyses were performed using
201B7 as the control. When using ONH-UCCiPS1 independently as a control, the same results were also confirmed.). m, n Magnified images of coronal
scanned MR images showing the morphological differences in the corpus callosum between Patient A (T2-weighted) and Patient B (T1-weighted). The
corpus callosum was not present in the MR images (M) of Patient A (with the p.N329S mutation), suggesting that the interhemispheric projection was
hypoplastic, unlike that in Patient B (with the p.R264C mutation). Poor neurite extension of patient-derived iPSCs was considered to correspond to the
patient’s phenotype and severity of the disease
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p.N329S TUBA1A, p.R264C TUBA1A was reported to
decrease the production of TUBA1A by disturbing
protein folding, which might be the reason for the
difference in disease severity; that is, the shortage of
TUBA1A caused by the p.R264C TUBA1A mutation
could be compensated for by other interchangeable α
tubulin isoforms via region-specific transcriptional
regulation [29–31]. Regional phenotypic differences in
TUBA1A mutation-associated lissencephaly also might
be partially explained by differences in the transcriptional
regulation of TUBA1A throughout the brain. Further in-
vestigation into TUBA1A regulation is needed to under-
stand the detailed mechanism of TUBA1A-associated
lissencephaly.
Finally, we hypothesized that lissencephaly may pro-
vide the key to understanding other neurodevelopmen-
tal disorders. For example, the pathological analysis of
postmortem brain tissue from a patient with autism
revealed a partial migration defect [32]. Moreover, the
MeCP2 gene, which is associated with syndromic autism
and Rett syndrome, is thought to modulate TUBA1A
expression [33].
Thus, we believe that an experimental system using
iPSC-derived neurospheres from cases of congenital
brain malformation would be useful for elucidating the
mechanism of the diseases and the development of the
human brain.
Conclusion
We established iPSCs derived from two TUBA1A-
associated lissencephaly patients and successfully mod-
eled one aspect of the pathogenesis of lissencephaly in
vitro using iPSC-NPCs and iPSC-derived neurons. The
disease modeling using iPSCs from patients with brain
malformation diseases helped us understand the mech-
anism underlying rare diseases and human brain
development.
Additional files
Additional file 1: Table S1. Primer sequences used in this study. *
These primers were used in quantitative PCR for pluripotent stem cell
markers. (DOCX 19 kb)
Additional file 2: Figure S1. (A) Characterization of umbilical cord
stromal cell-derived control iPSCs (ONH-UCCiPS1#1). ONH-UCCiPS1#1 is
morphologically similar to human embryonic stem cells on a mouse
embryonic fibroblast feeder. Immunocytochemistry showed that they
expressed the pluripotent stem cell markers OCT3/4 and NANOG
ubiquitously. (B) Quantitative RT-PCR for marker genes of pluripotent
stem cells (Relative to the expression in control human embryonic stem
cells KhES1, fold change ± SD, n = 3, technical duplicates) showed that
the generated iPSCs expressed the marker genes. (C) Conventional PCR
for the detection of persistence of the episomal vector confirmed no major
persistence of plasmid vectors (EP4 stands for the primer set designed using
detection of the episomal vector-specific sequence). (D) Teratoma formation
assay using subcutaneous transplantation in NOD/Shi-scid IL2Rg null (NOG)
mice (scale bar = 100 μm) showed that the patient-derived iPSCs could
differentiate into three germ layers. (TIF 19759 kb)
Additional file 3: Figure S2. (A-C) Immunocytochemistry for the
immature neuronal marker βIII tubulin and glial cell marker GFAP. Most of
the dissociated iPSC-NPCs were differentiated into neurons in serum-free
differentiation medium within 2 weeks. (D) Quantification of data from
immunocytochemical analyses showed that the dissociated iPSC-NPCs
were differentiated predominantly (>90 %) into βIII tubulin neurons in
2 weeks. GFAP-positive cells were very rarely (<1 %) observed in our
differentiation condition (mean ± SD, n = 3 technical duplicates of each
cell line, control; 201B7 and UCCiPS1#1, p.N329S; TUBA1A-iPS-A#1, A#3,
p.R264C; TUBA1A-iPS-B#1, B#2). No significant differences in the neurogenicity
and gliogenicity were observed between these cells (Welch’s t test).
(E) Quantitative RT-PCR showed that the expression of the glial marker
GFAP in the differentiated iPSC-NPCs was extremely low (mean ± SD, n = 3
technical duplicates of each cell line, control; 201B7 and UCCiPS1#1,
p.N329S; TUBA1A-iPS-A#1, A#3, p.R264C; TUBA1A-iPS-B#1, B#2). This result
was consistent with the data obtained from the immunocytochemical
analyses shown in Additional file 3: Figure S2A. In addition, there were no
significant differences in GFAP expression between these cell lines
(Welch’s t test). (F) Quantitative PCR showed that the immature neuronal
marker TUBB3 in the differentiated iPSC-NPCs was expressed in all the cell
lines, and that the differences were not statistically significant (Welch’s t test,
mean ± SD, n = 3 technical duplicates of each cell line, control; 201B7 and
UCCiPS1#1, p.N329S; TUBA1A-iPS-A#1, A#3, p.R264C; TUBA1A-iPS-B#1, B#2).
(TIF 19759 kb)
Additional file 4: Movie S1. Fluorescent neurosphere (201B7)
differentiation without glial cells. (AVI 25686 kb)
Additional file 5: Movie S2. Fluorescent neurosphere (201B7)
differentiation with glial cells. (AVI 30161 kb)
Additional file 6: Movie S3. Translocation-like movement in
differentiating fluorescent neurospheres (201B7) at high magnification.
(AVI 2472 kb)
Additional file 7: Movie S4. Neurite extension (201B7) with the glia-
supported neurites extension method. (AVI 1390 kb)
Additional file 8: Movie S5. Neurite extension (iPS-A) with the glia-
supported neurites extension method. (AVI 891 kb)
Additional file 9: Figure S3. Differentiating pPBCAG-TUBA1A-IRES-
AcGFP-transfected human NPCs. Measurements of AcGFP-positive
neurites from each cell (μm: mean ± SEM, n = 50, one-way ANOVA followed
by Dunnett’s test, **p< 0.01). Overexpression of mutant TUBA1A (p.N329S)
interfered with neurite extension in the human NSCs (scale bar = 200 μm).
(TIF 19759 kb)
Additional file 10: Supplementary method. (DOCX 72 kb)
Additional file 11: Movie S6. Neurite extension (iPS-B) with the glia-
supported neurites extension method. (AVI 1492 kb)
Abbreviation
NPC, neural progenitor cell; iPSC, induced pluripotent stem cells; SFEB,
serum-free embyoid body like aggregates; TUBA1A, alpha tubulin 1A; TUBB3,
beta III tubulin; GFAP, glial fibrillary acidic protein; BLBP, brain lipid-binding
protein; EGFP, enhanced green fluorescent protein; FOXG1, Forkhead box
protein G1; GBX2, gastrulation brain homeobox 2
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